S100A1 and acute myeloid leukemia: Several of the proteins are regarded as potential therapeutic targets in AML, including the integrin system [116,117,129] with the downstream MAP kinases [130,131,132,133,134,135,136], S100A molecules [121,122,137,138], and TLR2/4 with their downstream mediators [106,108], including the RHO GTPases [111,115,116,117,118,119,120,139,140].